Floatz logo

Larotrectinib

Mutation

Sun Yat-sen UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Mutation cohort.

Asset / SponsorPhaseRating
Everolimus
Fudan University
Phase 3B
Glecirasib
Sun Yat-sen University
Phase 2CCC
gsk1120212
Sun Yat-sen University
Phase 2CCC
VOLITINIB
Sun Yat-sen University
Phase 2CCC
Pralsetinib, trans-
Sun Yat-sen University
Phase 2CCC

View all 12 →

Same molecule, other indications

Larotrectinib is also rated in:

NTRK fusion positive cancerDormant
BB
Indicative ·
65 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
Locally Advanced Malignant Solid NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →